Video

Dr. O’Donnell on the Promise of Novel Targets in Multiple Myeloma

Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:56
Loaded: 0%
Stream Type LIVE
Remaining Time 0:56
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Betsy O'Donnell, MD, medical oncologist, Multiple Myeloma Disease Center, director of Lifestyle Medicine, Massachusetts General Hospital, discusses the promise of novel targets in multiple myeloma.

Significant progress in targeting B-cell maturation antigen (BCMA) has been made in multiple myeloma, O’Donnell says. Moreover, BCMA-directed therapies, such as CAR T-cell therapies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates, are FDA approved or under investigation in this setting, O’Donnell says.

However, the field is evaluating novel targets beyond BCMA for patients who become refractory to BCMA-directed treatments, O’Donnell says. For example, talquetamab, which targets GPRC5D, and cevostamab (BFCR4350A), which targets FcRH5, are under investigation, concludes O’Donnell.